乳腺癌转移抑制基因1(BRMS1)与宫颈癌变临床病理参数的关系研究
|
摘要
目的探讨乳腺癌转移抑制基因1(BRMS1)与宫颈癌变临床病理参数的关系。方法选取2017年4月22日～2018年4月22日期间我院收治的100例具有完整病理资料的宫颈疾病患者为实验对象,其中29例为轻度慢性宫颈炎,11例为CINⅠ级,10例为CINⅡ～Ⅲ级,50例为宫颈癌,对所有患者均进行BRMS1基因检测。结果从宫颈组织中的BRMS1表达角度分析,CINⅡ～Ⅲ期和CINⅠ期患者表达率无差异性(P>0.05),宫颈癌、CINⅡ～Ⅲ期、CINⅠ期患者与慢性宫颈炎患者相比,BRMS1蛋白阳性表达率下降(P<0.05)。从BRMS1表达的临床病理特征角度分析,不同浸润程度、FIGO分期、有无淋巴转移患者BRMS1表达阳性率存在明显差异(P<0.05),不同组织学分型、分化程度、肿瘤大小、年龄患者的BRMS1表达阳性率差异均无统计学意义(P>0.05)。结论宫颈癌变与BRMS1表达可呈负相关性,当BRMS1蛋白表达下降时,则意味着癌细胞处于转移、浸润、发展趋势。
Objective To explore the relationship between breast cancer metastasis suppressor 1(BRMS1) and clinical pathological parameters of cervical carcinogenesis. Methods A total of 100 patients with cervical disease with complete pathological data from April 22, 2017 to April 22, 2018 in our hospital were selected as subjects, 29 cases of whom were mild chronic cervicitis, 11 cases were CINⅠ, 10 cases were CINⅡ-Ⅲ grade, and 50 cases were cervical cancer.BRMS1 gene test was performed in all patients. Results From the perspective of BRMS1 expression in cervical tissues,there was no difference in the expression rates of patients with CINⅡ-Ⅲ and CINⅠ(P>0.05). The positive expression rate of BRMSI protein decreased in patients with cervical cancer, CINⅡ-Ⅲ, and CINⅠpatients, compared with that of patients with chronic cervicitis(P<0.05). From the perspective of clinicopathological features of BRMS1 expression,there was a significant difference in the positive rate of BRMS1 expression in patients with different degrees of infiltra tion, FIGO stage, with or without lymphatic metastasis(P<0.05). There was no difference in the positive rate of BRMS1 expression in patients with different histological types, differentiation, tumor size, and age(P>0.05). Conclusion Cervical carcinogenesis can be negatively correlated with BRMS1 expression. When BRMS1 protein expression is decreased, it means that cancer cells are in metastasis, infiltration and development trend.
Objective To explore the relationship between breast cancer metastasis suppressor 1(BRMS1) and clinical pathological parameters of cervical carcinogenesis. Methods A total of 100 patients with cervical disease with complete pathological data from April 22, 2017 to April 22, 2018 in our hospital were selected as subjects, 29 cases of whom were mild chronic cervicitis, 11 cases were CINⅠ, 10 cases were CINⅡ-Ⅲ grade, and 50 cases were cervical cancer.BRMS1 gene test was performed in all patients. Results From the perspective of BRMS1 expression in cervical tissues,there was no difference in the expression rates of patients with CINⅡ-Ⅲ and CINⅠ(P>0.05). The positive expression rate of BRMSI protein decreased in patients with cervical cancer, CINⅡ-Ⅲ, and CINⅠpatients, compared with that of patients with chronic cervicitis(P<0.05). From the perspective of clinicopathological features of BRMS1 expression,there was a significant difference in the positive rate of BRMS1 expression in patients with different degrees of infiltra tion, FIGO stage, with or without lymphatic metastasis(P<0.05). There was no difference in the positive rate of BRMS1 expression in patients with different histological types, differentiation, tumor size, and age(P>0.05). Conclusion Cervical carcinogenesis can be negatively correlated with BRMS1 expression. When BRMS1 protein expression is decreased, it means that cancer cells are in metastasis, infiltration and development trend.
引文
[1]王丽霞,毛俊,陶雅军,等.乳腺癌干细胞亚群中MMP-9和BRMS1的表达及其临床病理意义[J].临床与实验病理学杂志,2013,29(5):472-476.
[2]张雨禄,胡三元.乳腺癌转移抑制因子(BRMS1)在人乳腺癌细胞系中的表达受体研究[J].郑州大学学报(理学版),2014,46(1):94-97.
[3]夏菁,吕志栋,周沛红,等. BRMS1基因启动子甲基化修饰及其表达与三阴性乳腺癌转移的相关性[J].中华医学杂志,2017,97(44):3483-3487.
[4]姚亚峰,龚烨,李炳军,等.乳腺浸润性导管癌原发灶、腋窝淋巴结转移灶组织中SATB1和BRMS1的表达变化[J].山东医药,2015,15(43):76-77.
[5]胡祖健,徐海滨,任兴昌,等.乳腺癌转移抑制基因、尿激酶型纤溶酶原激活剂在乳腺癌组织中的表达[J].全科医学临床与教育,2015,21(2):132-134.
[6]李中林,梅鹏金,白津,等.乳腺癌转移抑制基因1通过金属蛋白酶组织抑制因子-2/基质金属蛋白酶-2途径抑制胶质瘤细胞侵袭[J].中华实验外科杂志,2013,30(11):2327-2329.
[7]张英,陈丽娟,刘永源,等.乳腺浸润性导管癌中SATB1和BRMS1的表达及与淋巴转移的相关性[J].广东医学,2015,15(4):532-537.
[8]李静,郭文治.乳腺癌转移抑制基因和运动相关蛋白基因在肝癌组织中的表达及其意义[J].中华实验外科杂志,2013,30(5):1042-1044.
[9]饶玉梅,陈刚,李留霞,等. BRMS1、整合素β1及pAKT在卵巢癌组织中的表达及临床意义[J].中国当代医药,2013,20(23):9-11.
[10]李中林,梅鹏金,白津,等.乳腺癌转移抑制基因1对胶质瘤细胞黏附和迁移的影响及其机制[J].中华实验外科杂志,2013,30(12):2606-2608.
[11]陈丽娟.乳腺浸润性导管癌中SATB1和BRMS1的表达及其与淋巴转移相关性研究[D].广东医学院,2013.
[12]段清,张晖. hTERT、hTERC基因在宫颈病变中的研究进展[J].临床心身疾病杂志,2015,21(z1):305-306.
[13]陈苗苗,吴均,朱雪琼,等.细胞分化相关基因在宫颈癌中的研究进展[J].医学研究杂志,2013,42(11):165-168.
[14]潘中亚,龙行华.乳腺癌转移抑制基因1表达与肿瘤发生发展相关性的Meta分析[J].国际肿瘤学杂志,2016,43(8):603-608.
[15]刘学智,南晶,李娟,等. FHIT基因甲基化及蛋白表达与HPV16感染在宫颈癌变中的交互效应[J].中华流行病学杂志,2016,37(6):858-862.
[16]卢丹,钱静,孙飞,等. PI3K、Akt、mTOR、p70S6K基因在宫颈癌变过程中的表达及相关性研究[J].中国现代医学杂志,2015,25(2):46-51.
[17]黄平,唐秋英,金瑛,等. Bcl-2蛋白在宫颈癌变组织中的表达及其与人乳头瘤病毒感染的关联性[J].海南医学,2013,24(1):3-5.
[18]陈春琴,邬素芳.高危型人类乳头瘤病毒E7促进宫颈癌变的分子机制研究进展[J].浙江临床医学,2017,19(4):770-772.
[19]林翠波,林安,何海新,等.抑癌基因P16和FHIT在宫颈病变组织中的表达及意义[J].中国妇幼健康研究,2017,28(11):1362-1363,1380.
[20]刘素琴,田瑞云,延海秀,等.高危型HPV和PTEN在宫颈癌变过程中的作用及相互关系[J].中国基层医药,2013,20(5):647-649.
[2]张雨禄,胡三元.乳腺癌转移抑制因子(BRMS1)在人乳腺癌细胞系中的表达受体研究[J].郑州大学学报(理学版),2014,46(1):94-97.
[3]夏菁,吕志栋,周沛红,等. BRMS1基因启动子甲基化修饰及其表达与三阴性乳腺癌转移的相关性[J].中华医学杂志,2017,97(44):3483-3487.
[4]姚亚峰,龚烨,李炳军,等.乳腺浸润性导管癌原发灶、腋窝淋巴结转移灶组织中SATB1和BRMS1的表达变化[J].山东医药,2015,15(43):76-77.
[5]胡祖健,徐海滨,任兴昌,等.乳腺癌转移抑制基因、尿激酶型纤溶酶原激活剂在乳腺癌组织中的表达[J].全科医学临床与教育,2015,21(2):132-134.
[6]李中林,梅鹏金,白津,等.乳腺癌转移抑制基因1通过金属蛋白酶组织抑制因子-2/基质金属蛋白酶-2途径抑制胶质瘤细胞侵袭[J].中华实验外科杂志,2013,30(11):2327-2329.
[7]张英,陈丽娟,刘永源,等.乳腺浸润性导管癌中SATB1和BRMS1的表达及与淋巴转移的相关性[J].广东医学,2015,15(4):532-537.
[8]李静,郭文治.乳腺癌转移抑制基因和运动相关蛋白基因在肝癌组织中的表达及其意义[J].中华实验外科杂志,2013,30(5):1042-1044.
[9]饶玉梅,陈刚,李留霞,等. BRMS1、整合素β1及pAKT在卵巢癌组织中的表达及临床意义[J].中国当代医药,2013,20(23):9-11.
[10]李中林,梅鹏金,白津,等.乳腺癌转移抑制基因1对胶质瘤细胞黏附和迁移的影响及其机制[J].中华实验外科杂志,2013,30(12):2606-2608.
[11]陈丽娟.乳腺浸润性导管癌中SATB1和BRMS1的表达及其与淋巴转移相关性研究[D].广东医学院,2013.
[12]段清,张晖. hTERT、hTERC基因在宫颈病变中的研究进展[J].临床心身疾病杂志,2015,21(z1):305-306.
[13]陈苗苗,吴均,朱雪琼,等.细胞分化相关基因在宫颈癌中的研究进展[J].医学研究杂志,2013,42(11):165-168.
[14]潘中亚,龙行华.乳腺癌转移抑制基因1表达与肿瘤发生发展相关性的Meta分析[J].国际肿瘤学杂志,2016,43(8):603-608.
[15]刘学智,南晶,李娟,等. FHIT基因甲基化及蛋白表达与HPV16感染在宫颈癌变中的交互效应[J].中华流行病学杂志,2016,37(6):858-862.
[16]卢丹,钱静,孙飞,等. PI3K、Akt、mTOR、p70S6K基因在宫颈癌变过程中的表达及相关性研究[J].中国现代医学杂志,2015,25(2):46-51.
[17]黄平,唐秋英,金瑛,等. Bcl-2蛋白在宫颈癌变组织中的表达及其与人乳头瘤病毒感染的关联性[J].海南医学,2013,24(1):3-5.
[18]陈春琴,邬素芳.高危型人类乳头瘤病毒E7促进宫颈癌变的分子机制研究进展[J].浙江临床医学,2017,19(4):770-772.
[19]林翠波,林安,何海新,等.抑癌基因P16和FHIT在宫颈病变组织中的表达及意义[J].中国妇幼健康研究,2017,28(11):1362-1363,1380.
[20]刘素琴,田瑞云,延海秀,等.高危型HPV和PTEN在宫颈癌变过程中的作用及相互关系[J].中国基层医药,2013,20(5):647-649.